NCT05359861Phase 2Terminated

Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

Study sponsor: Coherus Oncology, Inc. · CHRS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06-30Actual
Enrollment · participants30Actual
Source updated2026-10-01Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Nature, frequency, and severity of adverse events (AEs) per NCI CTCAE version 5.0 or higher Description: Summaries of AEs will be based on TEAEs. A TEAE is an AE that emerges or worsens in the period from the first dose of study drug to 30 days after the last dose of study drug (Lead-In Phase). Time frame: Up to 2 years Measure: Progression Free Survival (PFS) according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) Description: PFS according to RECIST v1.1 will be evaluated in patients receiving SRF388 in combination with atezolizumab plus bevacizumab compared to placebo in combination with atezolizumab plus bevacizumab (Randomized Phase). Time frame: Up to 2 years. After: Measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Description: A TEAE was defined as an AE that emerged or worsened in the period from the first dose of study drug to 30 days after the last dose of study drug. A summary of other non-serious AEs and all serious AEs, regardless of causality, is located in the Reported AE section. Time frame: Up to approximately 37 months.

Recruitment status changed

Before: Completed. After: Terminated.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview